A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.

J Psychopharmacol · 2016 · PMC4717319 · PMID 26645209

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

MMRM analysis found that between-group differences for lurasidone versus placebo were significant for the overall PANSS total ( p= 0.019) and CGI-S ( p =0.002) models; however, they did not reach statistical significance at the week 28 endpoint.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.